Theranos
2003
FOUNDED
OOB
STATUS
51-60
EMPLOYEES
Liquidation
LATEST DEAL TYPE
Description
Developer of bio-monitoring systems designed to facilitate small-sample collection, testing and rapid communication of diagnostic information.The company's proprietary miniLab created an integrated infrastructure for real-time testing, decision making and individualized therapy, enabling laboratories to process early detection and intervention.
Primary Industry
Monitoring Equipment
Primary Office
- 1701 Page Mill Road
- Palo Alto, CA 94304
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Theranos’s full profile, request a free trial.
Theranos Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Bankruptcy: Liquidation | 05-Sep-2018 | 00000 | Completed | Out of Business | ||
| 9. Debt - General | 23-Dec-2017 | 00000 | 00000 | Completed | Generating Revenue/Not Profitable | |
| 8. Secondary Transaction - Private | 27-Mar-2017 | 00000 | Completed | Generating Revenue/Not Profitable | ||
| 7. Later Stage VC (Series C3) | 01-Oct-2015 | 00000 | 000.00 | Cancelled | Generating Revenue/Not Profitable | |
| 6. Later Stage VC (Series C2) | 04-Feb-2014 | 00000 | 00000 | 00.00 | Completed | Generating Revenue/Not Profitable |
| 5. Later Stage VC (Series C1) | 28-Mar-2013 | 0000 | 00000 | 00.000 | Completed | Generating Revenue/Not Profitable |
| 4. Later Stage VC (Series C1) | 08-Jul-2010 | 0000 | 000.00 | 00.000 | Completed | Generating Revenue/Not Profitable |
| 3. Later Stage VC (Series C) | 15-Nov-2006 | 000.00 | 000.00 | 00000 | Completed | Startup |
| 2. Early Stage VC (Series B) | 16-Feb-2006 | $9.1M | $16M | 0000 | Completed | Startup |
| 1. Early Stage VC (Series A) | 30-Mar-2005 | $6.95M | $6.95M | 000.00 | Completed | Startup |
Theranos Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series C3 | 00,000,000 | 00.000000 | 000 | 000 | 00 | 000 | 0.000 | |
| Series C2 | 00,000,000 | 00.000000 | 000 | 000 | 00 | 000 | 00.000 | |
| Series C1 | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 0.000 | |
| Series C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series B | 54,162,965 | $0.000100 | $0.18 | $0.18 | 1x | $0.18 | 10.03% | |
| Series A | 46,320,045 | $0.000100 | $0.15 | $0.15 | 1x | $0.15 | 8.58% |
Theranos Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abingdon Health | Venture Capital-Backed | York, United Kingdom | 00 | 000.00 | 0000000000 0 | 000.00 |
| 0000000000 | Venture Capital-Backed | Austin, TX | 00 | 000.00 | 00000000000 | 000.00 |
| 00000 0000000 | Venture Capital-Backed | Saint Paul, MN | 00 | 000.00 | 00000000000 | 000.00 |
| 000000 | Formerly VC-backed | Union City, CA | 000 | 000.00 | 000000&0 | 000.00 |
| 00000 00000000000 | Venture Capital-Backed | Sydney, Australia | 00 | 000.00 | 000000000000 | 000.00 |
Theranos Executive Team (18)
9 Former Executives
You’re viewing 5 of 18 executives. Get the full list »